Juniper Pharmaceuticals, Inc. (JNP) Analysts See $-0.20 EPS; Entellus Medical (ENTL) Sellers Decreased By 3.59% Their Shorts

February 13, 2018 - By Dolores Ford

Analysts expect Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report $-0.20 EPS on March, 6.They anticipate $1.08 EPS change or 122.73% from last quarter’s $0.88 EPS. After having $-0.08 EPS previously, Juniper Pharmaceuticals, Inc.’s analysts see 150.00% EPS growth. The stock increased 5.95% or $0.4999 during the last trading session, reaching $8.8999. About 11,805 shares traded. Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has declined 42.39% since February 13, 2017 and is downtrending. It has underperformed by 59.09% the S&P500.

Entellus Medical Incorporated (NASDAQ:ENTL) had a decrease of 3.59% in short interest. ENTL’s SI was 2.23 million shares in February as released by FINRA. Its down 3.59% from 2.32 million shares previously. With 114,400 avg volume, 20 days are for Entellus Medical Incorporated (NASDAQ:ENTL)’s short sellers to cover ENTL’s short positions. The SI to Entellus Medical Incorporated’s float is 24.7%. The stock increased 0.12% or $0.03 during the last trading session, reaching $24.09. About 7,138 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since February 13, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $619.79 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. The rating was initiated by Deutsche Bank on Thursday, October 6 with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Monday, August 21 report. The firm has “Hold” rating given on Friday, December 8 by William Blair. BTIG Research initiated the stock with “Buy” rating in Tuesday, June 14 report. Piper Jaffray maintained the stock with “” rating in Tuesday, September 29 report. The stock of Entellus Medical, Inc. (NASDAQ:ENTL) has “Buy” rating given on Sunday, August 9 by Canaccord Genuity. Canaccord Genuity maintained Entellus Medical, Inc. (NASDAQ:ENTL) on Monday, October 16 with “Hold” rating.

Among 5 analysts covering Juniper Pharmaceuticals Inc (NASDAQ:JNP), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Juniper Pharmaceuticals Inc had 7 analyst reports since August 26, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 26 by TheStreet. The firm earned “Outperform” rating on Tuesday, January 26 by Northland Capital. Roth Capital initiated Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) rating on Tuesday, January 2. Roth Capital has “Buy” rating and $12.0 target. The stock of Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) has “Market Perform” rating given on Monday, January 9 by Bernstein. The firm has “Market Perform” rating by Northland Capital given on Thursday, August 18. The firm earned “Neutral” rating on Friday, August 19 by H.C. Wainwright.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>